Autoimmune-Rheum Dz (AIRD) flares occur in 10% w/ COVID vaccination, esp in pts w/ comorbidities, autoimmune morbidities & mental health disorders & Moderna vaccine. 3453 AIRD pts who recv Vax 9.5-11.3% had clinical flares (Arthritis 62% & fatigue 59%) https://t.co/C0WA2Znixl https://t.co/vXzL8XR7kd

Tofacitinib May Reduce Interstitial Lung Disease Risk in RA Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed. https://t.co/2DCn53Rk4z https://t.co/sZYhgfCU0E

Intrathecal Methotrexate for Cerebritis Dr. Jack Cush reviews the CV advantage to walking, the OA risk with running and the eczema-OA connection; these articles and journal reports from the past week on RheumNow. https://t.co/wTOehtaU27 https://t.co/8Xp0C6tqBe

Join RheumNow during the month of April as we discuss Women in Rheumatology, the XX Factor. Sign up to attend our series! https://t.co/e3AJKwnoWs https://t.co/cpUmsOVuAT

Network metaanalysis of 7 dietary RCTs in high risk CV pts (40 RCTs, 35 548 pts), showed only Mediterranean (OR 0.72) & low fat (OR 0.84) diet reduce all cause mortality; Med-diet also reduced CV mortality (0.55), stroke (0.65) & non-fatal MI (0.48) https://t.co/ibUknLlwOx https://t.co/zRtvXObvg3

RCT shows vitamin D does not improve psoriasis. 122 mild PSO pts (PASI=3.1) w/ mean low vit D levels 14.9 ng/mL; randomized to vit D (20KIU/wk) or placebo. At 4 mos, vit D levels rose to 30 w/ Rx, but no signif improvement in PASI change, MD global or DLQI https… https://t.co/OI5v1y5t0u

There are 27 US States where Nurse Practitioners have "Full Practice Authority" - including WA, OR, NV, ID, UT, MT, AZ, CO, WY, NM, ND, SD, NE, KS, Minn, NY, ME, VT, NH, MA, CT, RI, MD, DE, DC https://t.co/hA9Sd63bDW https://t.co/9MM6CTH4gX

203 Rheumatology Clinical trials .gov; after 30 mos 17% are unpublished. Published were more likely to be Phase 3 (57% v 29%) or have +primary outcome (65% vs 26%). Unpub authors cite ongoing preparation, sponsor issues, negative results https://t.co/zSxt0W9ZhB https://t.co/k9rCUSel3e

Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I & II trials show Week 16 50% HS Responses to be 48% and 52% (vs PBO 29% and 32%). >75% maintained response out to wk 48; at wk 48, a 75% HS response seen in 55%. https://t.co/ZxJylP7IUk https://t.co/Kmx1dkHycM

The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, regarding the marketing authorisation of deucravacitinib (Sotyktu) in the treatment of moderate to severe psoriasis based on the POETYK PSO-1 & POETYK PSO-2 RCTs https://t.co/KBIYSJVFqu . https://t.co/nzuHh6v0ua

Frunevetmab (Solensia), is a cat-specific mAb against nerve growth factor was FDA approved, for use in CATS, to treat the pain of osteoarthritis. CATS! https://t.co/mqmQ7jzbpj https://t.co/9FrIOAYJwA

Abbvie has completed a phase II upadacitinib vs combo elsubrutinib/upadacitinib ( ABBV-599) in active #SLE - M19-130 (SLEek) Phase 2 trial met the primary endpoint SRI-4 response and pred dose<=10 mg qd. No new safety signals - Phase III trial planned https://t.co/1ZiRX3jUGV https://t.co/k0a54QJ9Hi